Chimeric Therapeutics Posts Wider Half-Year Loss as Auditor Flags Going Concern Risk

The latest announcement is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).

Chimeric Therapeutics Limited reported a sharp increase in its half-year loss for the period ended 31 December 2025, with loss from ordinary activities after tax rising 292.5% to $11.2 million. Net tangible assets per security deteriorated to negative 0.09 cents from negative 0.45 cents a year earlier, no dividends were declared, there were no changes in controlled entities, and auditors issued an unmodified review opinion highlighting a material uncertainty regarding the group’s ability to continue as a going concern.

The absence of dividends and the increased losses underscore ongoing funding and profitability challenges typical of early-stage biotech companies, placing greater focus on Chimeric’s future capital management and clinical milestones. The going concern uncertainty flagged by the independent auditor may heighten risk perceptions among investors and other stakeholders while the company continues to pursue its development programs.

The most recent analyst rating on (AU:CHM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.

More about Chimeric Therapeutics Ltd.

Chimeric Therapeutics Limited is an Australia-listed biotechnology company focused on developing therapeutic products, with its shares traded on the ASX under the ticker CHM. The company operates in the clinical-stage biopharmaceutical sector and is engaged in research and development activities rather than generating recurring commercial revenue at this stage.

Technical Sentiment Signal: Sell

Current Market Cap: A$8.84M

Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.